Baidu
map

CIT 2014:冠脉分叉病变RESOLVE评分

2014-03-19 窦克非 医心网

研究背景 冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策

研究背景

冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策略对术后即刻和远期临床效果都有决定性作用,影响分叉病变介入策略选择的最主要因素是介入治疗过程中分支血管闭塞风险。目前对分支血管闭塞风险的评估尚无客观标准,介入术者只能依靠自身主观经验。

研究通过全面系统的筛选影响分支闭塞的危险因素,建立分支闭塞风险评分系统,全面评价多个危险因素共同作用下患者分支闭塞的风险大小,可为指导临床介入策略选择提供统一的客观标准。

研究设计

研究是一项大规模、单中心、回顾性研究,研究主要有以下特点。首先,研究涵盖的患者群广,入选患者时除采用选择性双支架的分叉病变患者排除外,其他所有累及重要分支的分叉病变患者均纳入其中。这样一项大规模、覆盖广的研究能够更好地为临床实践提供更完善、可靠的证据。其次,研究纳入的样本量大,本研究连续纳入了2012年1月至2012年7月在阜外医院行支架置入术的1537例分叉病变患者,共计1601例分叉病变,充足的样本量保障了本研究结论可靠性。再次,本研究系统的分析了可能影响分支闭塞的危险因素,如患者的临床情况、病史资料、冠状动脉造影特点和介入操作情况等,且创新性的发现并纳入了主支/分支直径比这一新变量。在全面分析既往分支闭塞危险因素的同时,提出了新的重要预测变量。最后,根据筛选出的分支闭塞危险因素,建立了RESOLVE分支闭塞风险评分系统。

RESOLVE评分系统的建立是基于患者的临床情况、病史资料、冠状动脉造影特点和介入操作情况等多方面的危险因素,综合评价多个危险因素共同作用下患者分支闭塞的风险大小,切实为临床决策提供客观依据。

研究结果

通过多因素回归分析,本研究最终筛选出包括主支/分支直径比等在内的6个危险因素,并据此建立了RESOLVE评分系统,用以评价分叉病变患者在介入治疗过程中分支闭塞的风险,进而指导介入策略选择。通过验证数据集检验,RESOLVE评分系统具有很好的区分度,能够准确地根据分支闭塞风险将分叉病变患者划分为高危、中危、低危患者。

RESOLVE研究结果将会在CIT2014会议上正式公布,让我们拭目以待!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738472, encodeId=7f7e1e38472a9, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793270, encodeId=a51a1e932709b, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Thu Jul 10 23:52:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493266, encodeId=b12e1493266ba, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557337, encodeId=60ea155e3374d, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738472, encodeId=7f7e1e38472a9, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793270, encodeId=a51a1e932709b, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Thu Jul 10 23:52:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493266, encodeId=b12e1493266ba, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557337, encodeId=60ea155e3374d, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738472, encodeId=7f7e1e38472a9, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793270, encodeId=a51a1e932709b, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Thu Jul 10 23:52:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493266, encodeId=b12e1493266ba, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557337, encodeId=60ea155e3374d, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]
    2014-03-21 hongbochen
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738472, encodeId=7f7e1e38472a9, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793270, encodeId=a51a1e932709b, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Thu Jul 10 23:52:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493266, encodeId=b12e1493266ba, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557337, encodeId=60ea155e3374d, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 21 01:52:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map